Evolution of chemotherapy with platinum compounds

Area of Science:

• Oncology
• Pharmacology

Background:

• Cancer remains a significant global health burden and cause of mortality.
• Cisplatin, a platinum-based chemotherapy agent, transformed cancer treatment but faces challenges.
• Limitations include severe side effects and the development of cisplatin-resistant tumors.

Purpose of the Study:

• To review advancements in cisplatin chemotherapy.
• To explore strategies for overcoming cisplatin resistance and toxicity.
• To highlight the evolving role of platinum-based anti-cancer agents.

Main Methods:

• Review of clinical strategies to mitigate cisplatin toxicity.
• Analysis of combination chemotherapy regimens involving cisplatin.
• Examination of cisplatin analogues for improved therapeutic profiles.

Main Results:

• Protective measures (hydration, dosing schedules) enable higher cisplatin doses and combat resistance.
• Combination therapies enhance cisplatin effectiveness and allow dose reduction, minimizing toxicity.
• Cisplatin analogues, such as carboplatin, offer reduced toxicity and improved activity against resistant cancers.

Conclusions:

• Ongoing evolution of platinum-based chemotherapy aims to maximize therapeutic benefits.
• Strategies discussed expand the scope and promise of platinum anti-cancer agents.
• Further research continues to refine cisplatin and its analogues for broader clinical application.